SCHEMBL26607185

SCHEMBL26607185

Cc1cc(C(C)(C)C)c(C)cc1-c1cc(=O)c2[nH]c(=O)ccc2[nH]1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP26A1 O43174 1/20 0.34
▸ CYP26B1 Q9NR63 1/20 0.34
▸ HPGD P15428 3/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ THRB P10828 1/20 0.32
▸ CA12 O43570 1/20 0.32
▸ CA9 Q16790 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.31
▸ NPC1 O15118 2/20 0.31
▸ LMNA P02545 2/20 0.31
▸ RAB9A P51151 2/20 0.31
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ ADORA1 P30542 1/20 0.31
▸ TP53 P04637 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26607318 0.83 CYP26A1 (0.41) CYP26A1CYP26B1HPGDMEN1ALDH1A1
SCHEMBL26847143 0.77 CTSV (0.52) HPGDMEN1ALDH1A1KMT2AKDM4E
SCHEMBL26725873 0.77 SMN1; SMN2 (0.55) HPGDMEN1ALDH1A1KMT2ATHRB
SCHEMBL26601604 0.75 — —
SCHEMBL30573081 0.74 MEN1 (0.36) CYP26A1CYP26B1HPGDMEN1ALDH1A1
SCHEMBL26607095 0.74 MEN1 (0.36) CYP26A1CYP26B1HPGDMEN1ALDH1A1
SCHEMBL26607148 0.73 KDM5A (0.38) HPGDRAB9AADORA1
SCHEMBL26847146 0.73 PDE10A (0.45) HPGDMEN1ALDH1A1KMT2ATHRB
SCHEMBL26725109 0.73 CHEK1 (0.36) —
SCHEMBL26724948 0.73 HPGD (0.35) HPGDMEN1ALDH1A1KMT2ATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4511114-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 — — EP disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN TRPV1, SCN3A, KCNN3 CYP26A1 1396/4885CYP26B1 1499/4885HPGD 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback